MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

NCT05735717 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Hematologic Malignancy
Acute Leukemia
Remission
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
AML
TP53
Intrachromosomal Amplification of Chromosome 21
Cytogenetic Abnormality
CNS Leukemia
Minimal Residual Disease
Myelodysplasia
Juvenile Myelomonocytic Leukemia
Somatic Mutation
PTPN11 Gene Mutation
N-RAS Gene Amplification
Neurofibromatosis 1
NF1 Mutation
CBL Gene Mutation
Monosomy 7
Chromosome Abnormality
Fetal Hemoglobin
Lymphoblastic Lymphoma
High Grade Non-Hodgkin's Lymphoma, Adult

Interventions

DRUG: Fludarabine
DRUG: Busulfan
DRUG: Melphalan
DRUG: Rituximab
DRUG: Levetiracetam
BIOLOGICAL: Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells
DRUG: Thymoglobulin
DRUG: Cyclophosphamide

Sponsor

Masonic Cancer Center, University of Minnesota